Ichor Biologics
Ichor Biologics is a NYC-based, pre-clinical biotechnology company dedicated to accelerating cures for infectious diseases through the development of antibody-based therapeutics. They leverage a novel high-throughput platform for the isolation and characterization of naturally occurring human antibodies, aiming to produce safe and effective therapeutics and establish strategic industry partnerships.
Industries
Nr. of Employees
small (1-50)
Patents
Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
US-9663553-B2
View Details
Integrated process for the production of therapeutics (human albumin, immunoglobulins, clotting factor VIII and clotting factor IX) from human plasma
US-9663553-B2
View DetailsServices
End-to-end discovery and preclinical optimization of human monoclonal antibodies against infectious pathogens, including candidate isolation, characterization and in vivo efficacy testing.
Design and deployment of assays to detect pathogen-specific immune responses, including long-term post-infection detection methods to identify protective immune signatures.
Application of machine learning tools to identify antibody binding sites and propose optimized antibody variants for improved pathogen targeting.
End-to-end discovery and preclinical optimization of human monoclonal antibodies against infectious pathogens, including candidate isolation, characterization and in vivo efficacy testing.
Design and deployment of assays to detect pathogen-specific immune responses, including long-term post-infection detection methods to identify protective immune signatures.
Application of machine learning tools to identify antibody binding sites and propose optimized antibody variants for improved pathogen targeting.
Expertise Areas
- Antibody discovery and engineering
- Infectious disease therapeutics
- Preclinical development and in vivo efficacy testing
- Immune-profiling assay development
Key Technologies
- High-throughput antibody screening
- Monoclonal antibody isolation and characterization
- Antigen production and presentation techniques
- Serological and pathogen-specific immunoassays
News & Updates
In findings published in Science Translational Medicine (Garrido et al.), scientists at Ichor Biologics, in collaboration with NIH and University of Concepción, demonstrate that Ichor's two lead antibody-based drugs protect animals against lethal hantavirus infections.
In May 2019, Ichor Biologics received a $300,000 grant from the NIH to develop broadly neutralizing antibodies against hantavirus infections.
In January 2017, Ichor was selected to participate in a 7-month mini biotech MBA program by NYC EDC.
In March 2017, in collaboration with the University of Concepcion, Ichor was awarded $250,000 by Chile's FONDEF to develop therapeutics against Andes hantavirus.
In December 2016, Ichor won a pitch competition in biotechnology industry.
In findings published in Science Translational Medicine (Garrido et al.), scientists at Ichor Biologics, in collaboration with NIH and University of Concepción, demonstrate that Ichor's two lead antibody-based drugs protect animals against lethal hantavirus infections.
In May 2019, Ichor Biologics received a $300,000 grant from the NIH to develop broadly neutralizing antibodies against hantavirus infections.
In January 2017, Ichor was selected to participate in a 7-month mini biotech MBA program by NYC EDC.
In March 2017, in collaboration with the University of Concepcion, Ichor was awarded $250,000 by Chile's FONDEF to develop therapeutics against Andes hantavirus.
In December 2016, Ichor won a pitch competition in biotechnology industry.